Prostate Cancer Coverage from Every Angle

FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

By: JNCCN 360 Staff
Posted: Wednesday, December 18, 2019

On December 16, 2019, Pfizer and Astellas Pharma announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer. With this approval, enzalutamide has now been approved in the treatment of three types of advanced prostate cancer: nonmetastatic and metastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.

The approval is based on results from the randomized phase III ARCHES trial, which evaluated 1,150 men with metastatic castration-sensitive prostate cancer and met its primary endpoint of radiographic progression-free survival. Data from the ARCHES trial demonstrated that the use of enzalutamide plus androgen-deprivation therapy significantly reduced the risk of radiographic disease progression or death by 61% compared with placebo plus androgen-deprivation therapy (n = 1,150; hazard ratio = 0.39 [95% confidence interval = 0.30–0.50]; P < .0001). Overall survival data were not mature at the time of final analysis of radiographic progression-free survival.

The safety analysis of the ARCHES trial is generally consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer. In the ARCHES trial, common adverse reactions that were reported more frequently in patients treated with enzalutamide plus androgen-deprivation therapy vs placebo plus androgen-deprivation therapy included hot flush (27% vs. 22%), asthenic conditions (24% vs. 20%), hypertension (8.0% vs. 5.6%), fractures (6.5% vs. 4.2%), and musculoskeletal pain (6.3% vs. 4.0%).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.